Clinical trial

Onvansertib + Paclitaxel In TNBC

NCT05383196

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2022-09-30

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2022-09-30Date precision: day

Registry last updated2026-02-11

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Breast Cancerunresolved

Invasive Breast Cancerunresolved

Unresectable Breast Carcinomaunresolved

Locally Advanced Breast Cancerunresolved

Metastatic Breast Cancerunresolved

Inflammatory Breast Cancerunresolved

Triple Negative Breast Cancer (TNBC)unresolved

Hormone Receptor/Growth Factor Receptor-Negative Breast Cancerunresolved

HER2-negative Breast Cancerunresolved

Hormone Receptor Negative Breast Carcinomaunresolved

Interventions

OnvansertibDRUG

PaclitaxelDRUG · verified · RxNorm: paclitaxel

Sponsors & collaborators

Antonio Giordano, MDlead sponsor

Cardiff Oncologycollaborator

Mapped research locations

BostonMassachusetts, United States3

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05383196 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.